U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

PubAg

Main content area

You searched for: Journal name Vaccine Remove constraint Journal name: Vaccine Subject term antigens Remove constraint Subject term: antigens
Start Over

Search

1,725  Search Results

« Previous | 1 - 50 of 1,725 |
Number of results to display per page

Search Results

1. Deceptive imprinting and immune refocusing in vaccine design

Author:
Tobin, Gregory J.; Trujillo, Jessie D.; Bushnell, Ruth V.; Lin, George; Chaudhuri, A.Ray; Long, Jinxue; Barrera, Jose; Pena, Lindomar; Grubman, Marvin J.; Nara, Peter L.
Source:
Vaccine 2008 v.26 no.49 pp. 6189-6199
Subject:
epitopes; Foot-and-mouth disease virus; host-pathogen relationships; Human immunodeficiency virus 1; Human rhinovirus; Influenza A virus; Caprine arthritis encephalitis virus; vaccine development; antigenic variation; antigen-antibody reactions; pathogens
Abstract:
... A large number of the world's most widespread and problematic pathogens evade host immune responses by inducing strain-specific immunity to immunodominant epitopes with high mutation rates capable of altering antigenic profiles. The immune system appears to be decoyed into reacting to these immunodominant epitopes that offer little cross protection between serotypes or subtypes. For example, durin ...
Handle:
10113/44051
DOI:
10.1016/j.vaccine.2008.09.080

2. Mucosal vaccination with a codon-optimized hemagglutinin gene expressed by attenuated Salmonella elicits a protective immune response in chickens against highly pathogenic avian influenza

Author:
Karen A. Liljebjelke; Daniel I. Petkov; Darrell R. Kapczynski
Source:
Vaccine 2010 v.28 no.27 pp. 4430-4437
ISSN:
0264-410X
Subject:
hemagglutination inhibition test; Salmonella Typhimurium; Western blotting; plasmids; vaccination; oral administration; assays; antibodies; recombinant proteins; gene expression; mucosa; sampling; blood serum; antigens; serotypes; White Leghorn; hemagglutinins; immune response; chickens; protein synthesis; Influenza A virus; live vaccines; codons; avian influenza
Abstract:
... The purpose of this study was to evaluate clinical protection from challenge conferred by two attenuated Salmonella enteria serovar typhimurium vaccine strains expressing the hemagglutinin (HA1) gene from a highly pathogenic avian influenza (HPAI) H5N1 (A/whooper swan/Mongolia/3/2005), under control of the anaerobically inducible nir15 promoter. Two-week-old White Leghorn chickens were immunized b ...
Handle:
10113/61343
DOI:
10.1016/j.vaccine.2010.04.009

3. A DNA vaccine encoding the E protein of West Nile Virus is protective and can be boosted by recombinant domain DIII

Author:
Anne Schneeweiss; Stefan Chabierski; Mathias Salomo; Nicolas Delaroque; Samiya Al-Robaiy; Thomas Grunwald; Kurt Bürki; Uwe G. Liebert; Sebastian Ulbert
Source:
Vaccine 2011 v.29 no.37 pp. 6352-6357
ISSN:
0264-410X
Subject:
T-lymphocytes; West Nile virus; antigens; birds; cell-mediated immunity; humans; immune response; mice; neutralization; neutralizing antibodies; plasmids; proteins; recombinant vaccines; vaccination; virus-like particles; viruses
Abstract:
... West Nile Virus (WNV) is an emerging pathogenic flavivirus with increasing distribution worldwide. Birds are the natural host of the virus, but also mammals, including humans, can be infected. In some cases, a WNV infection can be associated with severe neurological symptoms. All currently available WNV vaccines are in the veterinary sector, and there is a need to develop safe and effective immuni ...
DOI:
10.1016/j.vaccine.2011.04.116

4. A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR⁻/⁻ mice upon lethal virus challenge

Author:
Hani Boshra; Gema Lorenzo; Fernando Rodriguez; Alejandro Brun
Source:
Vaccine 2011 v.29 no.27 pp. 4469-4475
ISSN:
0264-410X
Subject:
antigens; T-lymphocytes; antibodies; plasmids; Rift Valley fever phlebovirus; mice; vaccination; animal models; genes; immune response; recombinant vaccines; vaccine development; viruses; glycoproteins
Abstract:
... Current vaccine candidates against Rift Valley fever virus (RVFV) incorporate the viral structural glycoproteins as antigens, since triggering antibody responses against them usually correlates with protection. Here, we have focused solely on the nucleoprotein of RVFV as a potential target for vaccine development. Previous studies in mouse models have already demonstrated that RVFV nucleoprotein c ...
DOI:
10.1016/j.vaccine.2011.04.043

5. A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors

Author:
Chunmei Cheng; Pooja Jain; Ilham Bettahi; Sukumar Pal; Delia Tifrea; Luis M. de la Maza
Source:
Vaccine 2011 v.29 no.38 pp. 6641-6649
ISSN:
0264-410X
Subject:
Chlamydia trachomatis; Neisseria gonorrhoeae; T-lymphocytes; Toll-like receptors; adjuvants; agonists; antigens; body weight changes; cell proliferation; cell-mediated immunity; flagellin; humoral immunity; immune response; immunization; interferon-gamma; intracellular signaling peptides and proteins; lipid A; lungs; mice; outer membrane proteins; pathogens; pneumonia; porins; vaccines
Abstract:
... Chlamydia trachomatis (Ct) is the most common sexually transmitted bacterial pathogen in the World and there is an urgent need for a vaccine to prevent these infections. To determine what type of adjuvant can better enhance the immunogenicity of a Chlamydia vaccine, we formulated the recombinant major outer membrane protein (Ct-rMOMP) with several ligands for Toll-like receptors (TLR) and the nucl ...
DOI:
10.1016/j.vaccine.2011.06.105
PubMed:
21742006
PubMed Central:
PMC3156873

6. A bivalent Vibrio harveyi DNA vaccine induces strong protection in Japanese flounder (Paralichthys olivaceus)

Author:
Yong-hua Hu; Li Sun
Source:
Vaccine 2011 v.29 no.26 pp. 4328-4333
ISSN:
0264-410X
Subject:
Paralichthys olivaceus; Vibrio harveyi; Vibrio parahaemolyticus; antibodies; antigens; aquaculture; blood serum; flounder; genes; kidneys; messenger RNA; models; muscle tissues; muscles; pathogens; plasmids; proteins; recombinant vaccines; spleen; survival rate; vaccination; vibriosis
Abstract:
... Vibrio harveyi is a severe aquaculture pathogen that can infect a large number of fish species. In previous studies, we have identified two protective immunogens, DegQ and Vhp1, from pathogenic V. harveyi strains. In this study, we examined the potentials of DegQ and Vhp1 as monovalent and bivalent DNA vaccines in a Japanese flounder (Paralichthys olivaceus) model. For this purpose, the DNA vaccin ...
DOI:
10.1016/j.vaccine.2011.04.021

7. A candidate dual vaccine against influenza and noroviruses

Author:
Ming Xia; Ming Tan; Chao Wei; Weiming Zhong; Leyi Wang; Monica McNeal; Xi Jiang
Source:
Vaccine 2011 v.29 no.44 pp. 7670-7677
ISSN:
0264-410X
Subject:
Orthomyxoviridae; antigens; chimerism; human influenza; immune response; immunization; mice; peptides; receptors; survival rate; vaccines
Abstract:
... The extracellular domain of the matrix protein 2 (M2e) of influenza viruses is highly conserved among all influenza A subtypes, making it a suitable target for a universal influenza vaccine. In this study, we demonstrated an enhanced immune response and protection of a chimeric M2e vaccine against influenza A viruses using our newly developed vaccine platform, the norovirus P particle, to present ...
DOI:
10.1016/j.vaccine.2011.07.139
PubMed:
21839795
PubMed Central:
PMC3190067

8. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis

Author:
Jaya Chakravarty; Subodh Kumar; Sonali Trivedi; Vijay K. Rai; Anup Singh; Jill A. Ashman; Elsa M. Laughlin; Rhea N. Coler; Stuart J. Kahn; Anna Marie Beckmann; Karen D. Cowgill; Steven G. Reed; Shyam Sundar; Franco M. Piazza
Source:
Vaccine 2011 v.29 no.19 pp. 3531-3537
ISSN:
0264-410X
Subject:
Leishmania donovani; T-lymphocytes; adults; agglutination tests; antigens; clinical trials; cytokines; immune response; interferon-gamma; vaccines; visceral leishmaniasis; volunteers
Abstract:
... Healthy Indian adult volunteers, with or without a history of leishmaniasis, were evaluated for evidence of previous infection with Leishmania donovani based on the direct agglutination test (DAT). Three cohorts of 6 DAT-negative and 6 DAT-positive subjects were enrolled in an open-label, dose-escalating, uncontrolled clinical trial and received three injections of the LEISH-F1+MPL-SE vaccine (con ...
DOI:
10.1016/j.vaccine.2011.02.096

9. A comparison of antibody responses to commercial equine influenza vaccines following primary vaccination of Thoroughbred weanlings—A randomised blind study

Author:
Sarah Gildea; Sean Arkins; Cathal Walsh; Ann Cullinane
Source:
Vaccine 2011 v.29 no.49 pp. 9214-9223
ISSN:
0264-410X
Subject:
Thoroughbred; antibodies; antigens; at-risk population; equine influenza; farms; hemagglutinins; hemolysis; horses; immune response; inactivated vaccines; issues and policy; marketing; recombinant vaccines; vaccination; viruses; weanlings; Ireland
Abstract:
... Many racing authorities, sales companies and equestrian bodies have mandatory vaccination policies for equine influenza (EI). The consequences of lack of vaccine efficacy include clinical disease, disruption to training programmes, the cancellation of equestrian events and the introduction of virus to susceptible populations. The correlation between antibody against the virus haemagglutinin and pr ...
DOI:
10.1016/j.vaccine.2011.09.101
CHORUS:
10.1016/j.vaccine.2011.09.101

10. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets

Author:
Brendan M. Giles; Ted M. Ross
Source:
Vaccine 2011 v.29 no.16 pp. 3043-3054
ISSN:
0264-410X
Subject:
Influenza A virus; amino acid sequences; antibodies; antigens; avian influenza; ferrets; human diseases; human population; mice; mortality; pandemic; vaccine development; virus-like particle vaccines; viruses
Abstract:
... Pandemic outbreaks of influenza are caused by the emergence of a pathogenic and transmissible virus to which the human population is immunologically naïve. Recent outbreaks of highly pathogenic avian influenza (HPAI) of the H5N1 subtype are of particular concern because of the high mortality rate (60% case fatality rate) and novel subtype. In order to develop a vaccine that elicits broadly reactiv ...
DOI:
10.1016/j.vaccine.2011.01.100
PubMed:
21320540
PubMed Central:
PMC3090662

11. A host-restricted viral vector for antigen-specific immunization against Lyme disease pathogen

Author:
Sa Xiao; Manish Kumar; Xiuli Yang; Mustafa Akkoyunlu; Peter L. Collins; Siba K. Samal; Utpal Pal
Source:
Vaccine 2011 v.29 no.32 pp. 5294-5303
ISSN:
0264-410X
Subject:
chickens; hamsters; Lyme disease; blood serum; antigens; humans; hosts; vaccines; pathogens; mice; Avian orthoavulavirus 1; Borrelia burgdorferi; membrane proteins; viruses; immunization; surface proteins; Primates
Abstract:
... Newcastle disease virus (NDV) is an avian virus that is attenuated in primates and is a potential vaccine vector for human use. We evaluated NDV as a vector for expressing selected antigens of the Lyme disease pathogen Borrelia burgdorferi. A series of recombinant NDVs were generated that expressed intracellular or extracellular forms of two B. burgdorferi antigens: namely, the basic membrane prot ...
DOI:
10.1016/j.vaccine.2011.05.010
PubMed:
21600949
PubMed Central:
PMC3138909

12. A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine

Author:
David W. Porter; Fiona M. Thompson; Tamara K. Berthoud; Claire L. Hutchings; Laura Andrews; Sumi Biswas; Ian Poulton; Eric Prieur; Simon Correa; Rosalind Rowland; Trudie Lang; Jackie Williams; Sarah C. Gilbert; Robert E. Sinden; Stephen Todryk; Adrian V.S. Hill
Source:
Vaccine 2011 v.29 no.43 pp. 7514-7522
ISSN:
0264-410X
Subject:
Plasmodium falciparum; antigens; humans; immune response; interferon-gamma; malaria; parasitemia; safety assessment; subunit vaccines; transgenes; vaccination; volunteers
Abstract:
... We examined the safety, immunogenicity and efficacy of a prime-boost vaccination regime involving two poxvirus malaria subunit vaccines, FP9-PP and MVA-PP, expressing the same polyprotein consisting of six pre-erythrocytic antigens from Plasmodium falciparum. Following safety assessment of single doses, 15 volunteers received a heterologous prime-boost vaccination regime and underwent malaria spor ...
DOI:
10.1016/j.vaccine.2011.03.083
PubMed:
21501642
PubMed Central:
PMC3195259

13. A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines

Author:
Anton P.J. Middelberg; Tania Rivera-Hernandez; Nani Wibowo; Linda H.L. Lua; Yuanyuan Fan; Graham Magor; Cindy Chang; Yap P. Chuan; Michael F. Good; Michael R. Batzloff
Source:
Vaccine 2011 v.29 no.41 pp. 7154-7162
ISSN:
0264-410X
Subject:
intranasal administration; freeze drying; antigens; antibodies; Mus musculus polyomavirus 1; bioreactors; geographical variation; manufacturing; chimerism; pathogens; mice; subcutaneous injection; vaccines; virus-like particles; immunization; Streptococcus; influenza; developed countries; Escherichia coli
Abstract:
... Studies on a platform technology able to deliver low-cost viral capsomeres and virus-like particles are described. The technology involves expression of the VP1 structural protein from murine polyomavirus (MuPyV) in Escherichia coli, followed by purification using scaleable units and optional cell-free VLP assembly. Two insertion sites on the surface of MuPyV VP1 are exploited for the presentation ...
DOI:
10.1016/j.vaccine.2011.05.075

14. A mucosal vaccination approach for herpes simplex virus type 2

Author:
Rebecca S. Tirabassi; Christopher I. Ace; Tatyana Levchenko; Vladimir P. Torchilin; Liisa K. Selin; Siwei Nie; Dennis L. Guberski; Kejian Yang
Source:
Vaccine 2011 v.29 no.5 pp. 1090-1098
ISSN:
0264-410X
Subject:
neutralization; survival rate; blood serum; antigens; DNA; mucosal immunity; Human alphaherpesvirus 2; Americans; sterilizing; vaccination; mice; viruses; neutralizing antibodies; immune response; CD4-positive T-lymphocytes; recombinant vaccines; synergism; glycoproteins
Abstract:
... An estimated 1 out of every 5 Americans is infected with herpes simplex virus type 2 (HSV-2). Efforts in developing a potent vaccine for HSV-2 have shown limited success. Here we describe a heterologous vaccination strategy for HSV-2 based on an intramuscular DNA prime followed by a liposome-encapsulated antigen boost delivered intranasally. Both portions of the vaccine express the immunogenic HSV ...
DOI:
10.1016/j.vaccine.2010.11.076
PubMed:
21134447
PubMed Central:
PMC3035179

15. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness

Author:
J.M. Langley; F. Aoki; B.J. Ward; A. McGeer; J.B. Angel; G. Stiver; I. Gorfinkel; D. Shu; L. White; B. Lasko; P. Dzongowski; K. Papp; M. Alexander; G. Boivin; L. Fries
Source:
Vaccine 2011 v.29 no.10 pp. 1921-1928
ISSN:
0264-410X
Subject:
adults; antigens; blood serum; cough; fever; headache; hemagglutinins; immunity; immunoglobulin A; influenza; muscles; nose; outer membrane proteins; pharyngitis; randomized clinical trials; relative risk; risk reduction; vaccination; vaccines
Abstract:
... A randomized placebo-controlled double-blind trial of a nasally administered inactivated trivalent influenza vaccine formulated with partially purified meningococcal outer membrane proteins (OMP-TIV) was conducted in 1349 healthy adults aged 18–64 years. Subjects received either vaccine containing 15μg of haemagglutinin (HA) of each of three influenza strains for the 2003–2004 season on days 0 and ...
DOI:
10.1016/j.vaccine.2010.12.100

16. A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity

Author:
Orli Even-Or; Aviva Joseph; Noga Itskovitz-Cooper; Sarit Samira; Eli Rochlin; Hagit Eliyahu; Itzik Goldwaser; Shobana Balasingam; Alex J. Mann; Rob Lambkin-Williams; Eli Kedar; Yechezkel Barenholz
Source:
Vaccine 2011 v.29 no.13 pp. 2474-2486
ISSN:
0264-410X
Subject:
Orthomyxoviridae; adverse effects; antigens; ceramides; cholesterol; ferrets; hemagglutination; influenza; interferon-gamma; interleukin-12; interleukin-2; lipid composition; mice; models; nose; pharmacokinetics; temperature; vaccines; viral load; weight loss
Abstract:
... We recently showed that lipid assemblies comprised of a novel polycationic sphingolipid (ceramide carbamoyl-spermine, CCS) are an effective adjuvant/carrier when complexed with cholesterol (CCS/C) for influenza and other vaccines administered parenterally and intranasally (i.n.) in mice. Here we expand these studies to ferrets, an established model of influenza infection. We also address the quest ...
DOI:
10.1016/j.vaccine.2011.01.009

17. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice

Author:
Milaid Granadillo; Maribel G. Vallespi; Aileen Batte; Osmany Mendoza; Yordanka Soria; Victoria M. Lugo; Isis Torrens
Source:
Vaccine 2011 v.29 no.5 pp. 920-930
ISSN:
0264-410X
Subject:
Limulus polyphemus; Papillomaviridae; T-lymphocytes; antigens; cell membranes; humans; mice; models; peptides; uterine cervical neoplasms; vaccination; vaccines
Abstract:
... The ultimate success of cancer vaccination is dependent upon the generation of tumor-specific CTLs. In this study, we designed and evaluated a novel fusion protein comprising a cell penetrating and immunostimulatory peptide corresponding to residues 32–51 of the Limulus polyphemus protein (LALF₃₂–₅₁) linked to human papillomavirus (HPV) 16 E7 antigen (LALF₃₂–₅₁–E7). We demonstrated that LALF₃₂–₅₁ ...
DOI:
10.1016/j.vaccine.2010.11.083

18. A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines

Author:
Aimin Tang; Fengsheng Li; Daniel C. Freed; Adam C. Finnefrock; Danilo R. Casimiro; Dai Wang; Tong-Ming Fu
Source:
Vaccine 2011 v.29 no.46 pp. 8350-8356
ISSN:
0264-410X
Subject:
immunity; neutralization; human diseases; serological surveys; antiviral properties; blood serum; antigens; neutralization tests; women; vaccines; congenital abnormalities; Macaca mulatta; cytopathogenicity; fetus; neutralizing antibodies; vaccination; clinical trials; females; Human betaherpesvirus 5
Abstract:
... Neutralizing antibodies are considered an important component of protective immunity against congenital infection of human cytomegalovirus (HCMV), a frequently cited cause of birth defects. An effective HCMV vaccine is desired to induce potent neutralizing antibodies in seronegative females, so that the viral transmission to fetus would be blocked if the women contracted HCMV infections during the ...
DOI:
10.1016/j.vaccine.2011.08.086

19. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus

Author:
Dubravka Grdic Eliasson; Anja Helgeby; Karin Schön; Caroline Nygren; Karim El-Bakkouri; Walter Fiers; Xavier Saelens; Karin Bengtsson Lövgren; Ida Nyström; Nils Y. Lycke
Source:
Vaccine 2011 v.29 no.23 pp. 3951-3961
ISSN:
0264-410X
Subject:
CD4-positive T-lymphocytes; Orthomyxoviridae; adjuvants; animal models; antigens; blood serum; freeze drying; immune response; immunization; immunoglobulin A; immunoglobulin G; immunomodulation; influenza; intranasal administration; morbidity; mortality; pandemic; vaccines
Abstract:
... Here we demonstrate that by using non-toxic fractions of saponin combined with CTA1-DD we can achieve a safe and above all highly efficacious mucosal adjuvant vector. We optimized the construction, tested the requirements for function and evaluated proof-of-concept in an influenza A virus challenge model. We demonstrated that the CTA1-3M2e-DD/ISCOMS vector provided 100% protection against mortalit ...
DOI:
10.1016/j.vaccine.2011.03.090

20. A novel retinoic acid, catechin hydrate and mustard oil-based emulsion for enhanced cytokine and antibody responses against multiple strains of HIV-1 following mucosal and systemic vaccinations

Author:
Mingke Yu; Michael Vajdy
Source:
Vaccine 2011 v.29 no.13 pp. 2429-2436
ISSN:
0264-410X
Subject:
Human immunodeficiency virus 1; adjuvants; antibodies; antigens; catechin; cytokines; emulsions; immune response; mice; mustard oil; pathogens; retinoic acid; vaccine development; vaccines; vitamin A
Abstract:
... Non-replicating protein- or DNA-based antigens generally require immune-enhancing adjuvants and delivery systems. It has been particularly difficult to raise antibodies against gp120 of HIV-1, which constitutes an important approach in HIV vaccine design. While almost all effort in adjuvant research has focused on mimicking the pathogens and the danger signals they engender in the host, relatively ...
DOI:
10.1016/j.vaccine.2011.01.024
PubMed:
21272602
PubMed Central:
PMC3055955

21. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems

Author:
Alexander R. Precioso; João L. Miraglia; Lúcia Maria A. Campos; Alessandra C. Goulart; Maria do Carmo S.T. Timenetsky; Maria Regina A. Cardoso; Expedito Luna; Gabriella Mondini; José da S. Guedes; Isaias Raw
Source:
Vaccine 2011 v.29 no.48 pp. 8974-8981
ISSN:
0264-410X
Subject:
Bordetella pertussis; adults; aluminum hydroxide; antigens; headache; hemagglutinins; immune response; influenza; injection site; lipid A; seroconversion; squalene; vaccination; vaccines
Abstract:
... METHODS: We conducted a phase I, multicenter, randomized, double-blind, placebo-controlled, multi-arm (10) parallel study involving healthy adults to evaluate the safety and immunogenicity of influenza A (H1N1) 2009 non-adjuvanted and adjuvanted candidate vaccines. Subjects received two intramuscular injections of one of the candidate vaccines administered 21 days apart. Antibody responses were me ...
DOI:
10.1016/j.vaccine.2011.09.040

22. A phase III randomized, controlled study to assess the immunogenicity and tolerability of DTPw–HBV–Hib, a liquid pentavalent vaccine in Indian infants

Author:
Hitt Sharma; Sangita Yadav; Sanjay Lalwani; Vijay Gupta; Subhash Kapre; Suresh Jadhav; Anita Chakravarty; Sameer Parekh; Sonali Palkar
Source:
Vaccine 2011 v.29 no.13 pp. 2359-2364
ISSN:
0264-410X
Subject:
antigens; blood; childhood; immune response; infants; injection site; markets; pain; vaccination; vaccines; India
Abstract:
... Immunogenicity and tolerability of two liquid pentavalent vaccines, Pentavac® (new vaccine), and Easyfive® (available in the market) was assessed in a multicentre study in India. In all, 484 infants aged 6–8 weeks were enrolled, and their blood samples were assessed prior to the first dose and one month after the third dose. A 100% seroprotection rate was achieved with both vaccines’ antigens, exc ...
DOI:
10.1016/j.vaccine.2011.01.054

23. A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax

Author:
Jyotsna Gorantala; Sonam Grover; Divya Goel; Amit Rahi; Sri Krishna Jayadev Magani; Subhash Chandra; Rakesh Bhatnagar
Source:
Vaccine 2011 v.29 no.27 pp. 4521-4533
ISSN:
0264-410X
Subject:
Agrobacterium; Bacillus anthracis; Escherichia coli; animal models; anthrax; antibodies; antigens; antiserum; chloroplasts; gene expression; genes; immunity; immunization; immunoglobulin G; macrophages; mice; neutralization; plant response; spores; vaccines
Abstract:
... The currently available anthrax vaccines are limited by being incompletely characterized, potentially reactogenic and have an expanded dosage schedule. Plant based vaccines offer safe alternative for vaccine production. In the present study, we expressed domain IV of Bacillus anthracis protective antigen gene [PA(dIV)] in planta (by nuclear agrobacterium and chloroplast transformation) and E. coli ...
DOI:
10.1016/j.vaccine.2011.03.082

24. A single point mutation in framework region 3 of heavy chain affects viral neutralization dynamics of single-chain Fv against bovine herpes virus type 1

Author:
Madhuri Koti; Eva Nagy; Azad K. Kaushik
Source:
Vaccine 2011 v.29 no.45 pp. 7905-7912
ISSN:
0264-410X
Subject:
neutralization; cattle diseases; Bovine alphaherpesvirus 1; etiological agents; antigens; neutralization tests; cattle; vaccines; amino acids; viruses; mutants; fluorescent antibody technique; point mutation
Abstract:
... We constructed functional recombinant single chain Fv (scFv) against bovine herpes virus type 1 (BoHV-1), aetiological agent of respiratory and genital diseases in cattle for which available vaccines do not provide adequate protection. The scFv against BoHV-1 with 18 amino acid long flexible linker (scFv3-18L; monomeric form) recognized target antigen and, also, neutralized BoHV-1 in vitro. A comp ...
DOI:
10.1016/j.vaccine.2011.08.077

25. A stable plasmid system for heterologous antigen expression in attenuated Vibrio anguillarum

Author:
Yan Xiao; Qin Liu; Hao Chen; Yuanxing Zhang
Source:
Vaccine 2011 v.29 no.40 pp. 6986-6993
ISSN:
0264-410X
Subject:
Danio rerio; Edwardsiella tarda; Vibrio anguillarum; animal models; antigens; bacteria; genes; glyceraldehyde-3-phosphate dehydrogenase; larvae; live vaccines; pathogens; plasmids; protein synthesis; replicon; turbot; vaccination
Abstract:
... To stably synthesize heterologous protein in an attenuated Vibrio anguillarum strain (MVAV6203) for potential multivalent live vaccine application, plasmids with different replicons were used to construct protein expression systems in this work. The gfp fragment under control of a strict low-iron-regulated promoter Pᵥᵢᵤₐ was inserted into seven plasmids with varied replicons derived from pAT153, p ...
DOI:
10.1016/j.vaccine.2011.07.036

26. A therapeutic anti-Streptococcus mutans monoclonal antibody used in human passive protection trials influences the adaptive immune response

Author:
Rebekah A. Robinette; Monika W. Oli; William P. McArthur; L. Jeannine Brady
Source:
Vaccine 2011 v.29 no.37 pp. 6292-6300
ISSN:
0264-410X
Subject:
Streptococcus mutans; adaptive immunity; adhesins; antigen-antibody complex; antigens; bacteria; blood serum; clinical trials; crystal structure; humans; immunization; immunomodulators; mechanism of action; mice; monoclonal antibodies; pathogens; plantibodies; tobacco; vaccines
Abstract:
... The adhesin known as Antigen I/II, P1 or PAc of the cariogenic dental pathogen Streptococcus mutans is a target of protective immunity and candidate vaccine antigen. Previously we demonstrated that immunization of mice with S. mutans complexed with anti-AgI/II monoclonal antibodies (MAbs) resulted in changes in the specificity, isotype and functionality of elicited anti-AgI/II antibodies in the se ...
DOI:
10.1016/j.vaccine.2011.06.027
PubMed:
21704107
PubMed Central:
PMC3156276

27. A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori

Author:
Carl-Fredrik Flach; Natascha Svensson; Margareta Blomquist; Annelie Ekman; Sukanya Raghavan; Jan Holmgren
Source:
Vaccine 2011 v.29 no.6 pp. 1235-1241
ISSN:
0264-410X
Subject:
Helicobacter pylori; antigens; detergents; humans; immune response; interleukin-17; lipoproteins; mice; models; stomach; synergism; toxicity; vaccination; vaccines
Abstract:
... HpaA is a Helicobacter pylori-specific lipoprotein that has been shown to be an effective protective antigen for mucosal vaccination against H. pylori infection in mice. However, detergents are needed for the purification of full-length HpaA (HpaAfᵤₗₗ), which might confer toxicity, thus making HpaAfᵤₗₗ unsuitable for use in a human vaccine. We here describe a recombinantly produced truncated versi ...
DOI:
10.1016/j.vaccine.2010.11.088

28. AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats

Author:
Akihito Sawada; Katsuhiro Komase; Tetsuo Nakayama
Source:
Vaccine 2011 v.29 no.7 pp. 1481-1490
ISSN:
0264-410X
Subject:
antigens; histopathology; infants; inflammation; models; monkeys; neutralizing antibodies; phenotype; pneumonia; protective effect; rats; vaccines; viruses
Abstract:
... Respiratory syncytial virus (RSV) is the most common cause of respiratory infection in infants, and no vaccine is available. In this report, recombinant AIK-C measles vaccines, expressing the RSV G or F protein of subgroup A (MVAIK/RSV/G or F), were investigated as a RSV vaccine candidate. MVAIK/RSV/G or F had the original ts phenotype and expressed RSV/G or F protein. Cross-reactive neutralizing ...
DOI:
10.1016/j.vaccine.2010.12.028
PubMed:
21185852
PubMed Central:
PMC7127509

29. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity

Author:
Sandra Morel; Arnaud Didierlaurent; Patricia Bourguignon; Sophie Delhaye; Benoît Baras; Valérie Jacob; Camille Planty; Abdelatif Elouahabi; Pol Harvengt; Harald Carlsen; Anders Kielland; Patrick Chomez; Nathalie Garçon; Marcelle Van Mechelen
Source:
Vaccine 2011 v.29 no.13 pp. 2461-2473
ISSN:
0264-410X
Subject:
mechanism of action; antigens; humans; innate immunity; adaptive immunity; injection site; monocytes; interleukin-6; vaccines; alpha-tocopherol; granulocytes; antigen-presenting cells; mice; pandemic; emulsions; influenza; squalene; lymph nodes; aluminum hydroxide
Abstract:
... AS03 is an Adjuvant System (AS) containing α-tocopherol and squalene in an oil-in-water (o/w) emulsion. AS03 has been considered for the development of pandemic and seasonal influenza vaccines. Key features of AS03's mode of action were investigated in vivo in mice and ex vivo in human cells. AS03's adjuvant activity was superior to that of aluminium hydroxide and required the spatio-temporal co-l ...
DOI:
10.1016/j.vaccine.2011.01.011

30. Aerosol delivery of virus-like particles to the genital tract induces local and systemic antibody responses

Author:
Zoe Hunter; Ebenezer Tumban; Agnieszka Dziduszko; Bryce Chackerian
Source:
Vaccine 2011 v.29 no.28 pp. 4584-4592
ISSN:
0264-410X
Subject:
Papillomaviridae; Pseudovirus; aerosols; animal models; antibodies; antigens; bacteriophages; coat proteins; female genitalia; humans; immunization; immunoglobulin A; immunoglobulin G; mice; mucosal immunity; sexually transmitted diseases; vaccines; virus-like particles
Abstract:
... The induction of mucosal immune responses in the genital tract may be important for increasing the effectiveness of vaccines for sexually transmitted infections (STIs). In this study, we asked whether direct immunization of the mouse genital tract with a non-replicating virus-like particle (VLP)-based vaccine could induce local mucosal as well as systemic antibody responses. Using VLPs derived fro ...
DOI:
10.1016/j.vaccine.2011.04.051
PubMed:
21549786
PubMed Central:
PMC3114090

31. Age-related changes in durability and function of vaccine-elicited influenza-specific CD4⁺ T-cell responses

Author:
Yolanda D. Mahnke; Areej Saqr; Staci Hazenfeld; Rebecca C. Brady; Mario Roederer; Ramu A. Subbramanian
Source:
Vaccine 2011 v.29 no.47 pp. 8606-8614
ISSN:
0264-410X
Subject:
CD4-positive T-lymphocytes; CD8-positive T-lymphocytes; antigens; cytokines; durability; elderly; hemagglutinins; immunity; influenza; interferon-gamma; phenotype; vaccination; vaccines; young adults
Abstract:
... The major antigenic component of licensed influenza vaccines, hemagglutinin (HA), elicits predominantly type-specific antibody responses, thus necessitating frequent antigenic updates to the annual vaccine. However, accumulating evidence suggests that influenza vaccines can also induce significant cross-reactive T-cell responses to highly divergent, heterosubtypic HA antigens not included in the v ...
DOI:
10.1016/j.vaccine.2011.09.019
PubMed:
21939709
PubMed Central:
PMC3224983

32. An alternative renewable source of squalene for use in emulsion adjuvants

Author:
Luis A. Brito; Michelle Chan; Barbara Baudner; Simona Gallorini; George Santos; Derek T. O’Hagan; Manmohan Singh
Source:
Vaccine 2011 v.29 no.37 pp. 6262-6268
ISSN:
0264-410X
Subject:
Neisseria meningitidis; adjuvants; animals; antibacterial properties; antibodies; antigens; blood serum; enzyme-linked immunosorbent assay; hemagglutinins; immune response; immunization; influenza; nanoemulsions; oils; squalene; vaccines; viscosity; Europe
Abstract:
... Emulsions have been used to boost immunogenicity of antigens since the discovery of complete Freunds adjuvant. Optimization to reduce reactogenicity of emulsion adjuvants lead to the development of oil in water emulsions based on squalene. MF59 is an oil-in-water emulsion that is a component of an approved influenza product in Europe. Currently MF59 is manufactured from squalene derived from an an ...
DOI:
10.1016/j.vaccine.2011.06.067

33. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children

Author:
Markus Knuf; Anna Pantazi-Chatzikonstantinou; Ulrich Pfletschinger; Irmingard Tichmann-Schumann; Hartwig Maurer; Lothar Maurer; Thomas Fischbach; Henrike Zinke; Heidemarie Pankow-Culot; Vassiliki Papaevangelou; Veronique Bianco; Marie Van der Wielen; Jacqueline M. Miller
Source:
Vaccine 2011 v.29 no.25 pp. 4264-4273
ISSN:
0264-410X
Subject:
antigens; children; immune response; risk; seroprevalence; serotypes; vaccination; vaccines
Abstract:
... Tetravalent meningococcal serogroups ACWY conjugate vaccines will provide an advantage to those at most risk of invasive meningococcal disease; namely young children. Co-administration of ACWY-TT with DTaP-HBV-IPV/Hib was assessed in a randomized trial in 793 children aged 12–23 months. Pre-specified criteria for non-inferiority of immunogenicity following co-administration versus separate ACWY-TT ...
DOI:
10.1016/j.vaccine.2011.03.009

34. Antibody forming cells and plasmablasts in peripheral blood in CVID patients after vaccination

Author:
Zita Chovancova; Marcela Vlkova; Jiri Litzman; Jindrich Lokaj; Vojtech Thon
Source:
Vaccine 2011 v.29 no.24 pp. 4142-4150
ISSN:
0264-410X
Subject:
immunoglobulin G; immunoglobulin M; blood serum; antibody formation; antigens; immunosuppression; antibodies; tetanus; vaccines; flow cytometry; blood flow; immunoglobulin A; patients; vaccination; volunteers; B-lymphocytes
Abstract:
... Common variable immunodeficiency (CVID), the most frequent primary antibody disorder, is characterized by hypogammaglobulinaemia and impaired antibody production. Poor vaccination response is essential for the diagnosis of CVID. Their under laying defects remain to be elucidated. Routine determination of antibody production in serum from CVID patients after vaccination and investigation of B cell ...
DOI:
10.1016/j.vaccine.2011.03.087

35. Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations

Author:
Aleksandra Gracia; Monika Polewicz; Scott A. Halperin; Robert E.W. Hancock; Andrew A. Potter; Lorne A. Babiuk; Volker Gerdts
Source:
Vaccine 2011 v.29 no.8 pp. 1595-1604
ISSN:
0264-410X
Subject:
Bordetella pertussis; adjuvants; adults; antigens; blood serum; immune response; immunoglobulin G; immunomodulators; mice; neonates; oligodeoxyribonucleotides; pathogens; peptides; vaccination; vaccines; whooping cough
Abstract:
... A balanced or Th-1 type immune response is required for effective clearance of many pathogens such as Bordetella pertussis, the causative agent of whooping cough. Since current acellular pertussis vaccines induce limited Th-1 type immune responses, novel vaccine formulations are needed to induce protective immunity in the infant in the earliest stages of life. Here, we developed a novel vaccine pl ...
DOI:
10.1016/j.vaccine.2010.12.083

36. Antigen-specific enhancement of natural human IgG antibodies to phosphatidylcholine, phosphatidylglycerol, phosphatidylinositol-4-phosphate, cholesterol, and lipid A by a liposomal vaccine containing lipid A

Author:
Gary R. Matyas; Carl R. Alving
Source:
Vaccine 2011 v.29 no.32 pp. 5137-5144
ISSN:
0264-410X
Subject:
Plasmodium falciparum; adsorption; antibodies; antigens; ceramides; cholesterol; enzyme-linked immunosorbent assay; gangliosides; germ cells; humans; immune response; immunization; immunoglobulin G; infectious diseases; lipid A; phosphatidylcholines; vaccines; volunteers
Abstract:
... Natural IgG antibodies (NA) to lipids are ubiquitously distributed in sera of healthy humans and are believed to serve beneficial functions. Although NA to lipids generally exhibit germ line or near germ line binding specificities, the antibodies commonly increase transiently in the acute phases of most, if not all, infectious diseases and may serve as a first line of defense. In order to determin ...
DOI:
10.1016/j.vaccine.2011.05.042

37. Antisense oligonucleotide inhibits avian influenza virus H5N1 replication by single chain antibody delivery system

Author:
Tao Zhang; Ping-sen Zhao; Wei Zhang; Meng Liang; Yu-wei Gao; Song-tao Yang; Tie-cheng Wang; Chuan Qin; Cheng-yu Wang; Xian-zhu Xia
Source:
Vaccine 2011 v.29 no.8 pp. 1558-1564
ISSN:
0264-410X
Subject:
Influenza A virus; antigens; antiviral properties; fluorescein; fluorescent antibody technique; genes; humans; lungs; mice; oligonucleotides; pandemic; poultry; reverse transcriptase polymerase chain reaction; vaccines; viral load; virus replication; wild birds
Abstract:
... H5N1 avian influenza virus (AIV) causes widespread infections in poultry and wild birds, and has the potential to emerge as a pandemic threat to human. Antisense oligonucleotides (AS ODNs) are highly effective at inhibiting gene replication. Antibody-mediated delivery is a novel approach to target specific cells and tissues. In this study, we designed and synthesized three AS ODNs (PA4, PA492 and ...
DOI:
10.1016/j.vaccine.2010.12.088

38. Antitumour immunity mediated by mannan-modified adenovirus vectors expressing VE-cadherin

Author:
Zhiwei Zhao; Yaqin Yao; Zhenyu Ding; Xi Chen; Ke Xie; Yan Luo; Jiaming Zhang; Xiancheng Chen; Xiaohua Wu; Jianrong Xu; Jumei Zhao; Ting Niu; Jiyan Liu; Qiu Li; Wei Zhang; Yanjun Wen; Jingmei Su; Bing Hu; Hong Bu; Yuquan Wei; Yang Wu
Source:
Vaccine 2011 v.29 no.25 pp. 4218-4224
ISSN:
0264-410X
Subject:
T-lymphocytes; Western blotting; adhesion; angiogenesis; antibodies; antigens; cadherins; chromium; cytotoxicity; enzyme-linked immunosorbent assay; immune response; immunohistochemistry; immunotherapy; mice; models; neoplasms; splenocytes; vaccines
Abstract:
... Anti-angiogenesis represents an indispensible strategy for cancer therapy. As a strictly endothelial-specific adhesion molecule, vascular endothelial cadherin (VE-cadherin, VE-cad) is a promising anti-angiogenesis target. In this study a recombinant adenovirus vector modified with mannan was used to deliver VE-cad (AdVEC-m) and we tried to explore its feasibility as an antitumour agent in mouse ca ...
DOI:
10.1016/j.vaccine.2011.03.109

39. Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs

Author:
Abdolreza Advani; Lennart Gustafsson; Christina Åhrén; Frits R. Mooi; Hans O Hallander
Source:
Vaccine 2011 v.29 no.18 pp. 3438-3442
ISSN:
0264-410X
Subject:
Bordetella pertussis; alleles; antigens; children; infectious diseases; pertussis toxin; serotypes; vaccination; vaccines; virulence; Sweden
Abstract:
... After introduction of a mono-component vaccine, containing only pertussis toxoid (PT), the incidence of pertussis was significantly higher in the Gothenburg area among children during the period October 1, 1997 until end of 2006 compared to the Rest of Sweden where a vaccine containing PT and two other pertussis antigens was used. To investigate a possible cause of this difference, the Bordetella ...
DOI:
10.1016/j.vaccine.2011.02.070

40. Archaeosomes with encapsulated antigens for oral vaccine delivery

Author:
Zhengrong Li; Lihui Zhang; Wenqiang Sun; Qian Ding; Yongtai Hou; Yuhong Xu
Source:
Vaccine 2011 v.29 no.32 pp. 5260-5266
ISSN:
0264-410X
Subject:
CD8-positive T-lymphocytes; Sulfolobus; antigens; cell proliferation; encapsulation; fluorescence; gastrointestinal system; immune response; immunization; immunoglobulin A; immunoglobulin G; oral administration; ovalbumin; vaccines
Abstract:
... Traditional phosphodiester lipid vesicles (liposomes) are not stable and could be easily degraded in the gastrointestinal (GI) tract. We prepared a novel lipid based oral delivery system: archaeosomes, made of the polar lipid fraction E (PLFE) extracted from Sulfolobus acidocaldarius, and tested their immunogenic potentials as oral vaccine delivery vehicles. Our study showed that the archaeosomes ...
DOI:
10.1016/j.vaccine.2011.05.015

41. ArtinM, a d-mannose-binding lectin from Artocarpus integrifolia, plays a potent adjuvant and immunostimulatory role in immunization against Neospora caninum

Author:
Mariana R.D. Cardoso; Caroline M. Mota; Dâmaso P. Ribeiro; Fernanda M. Santiago; Julianne V. Carvalho; Ester C.B. Araujo; Neide M. Silva; Tiago W.P. Mineo; Maria C. Roque-Barreira; José R. Mineo; Deise A.O. Silva
Source:
Vaccine 2011 v.29 no.49 pp. 9183-9193
ISSN:
0264-410X
Subject:
Artocarpus heterophyllus; Neospora caninum; antigens; brain; cattle; cytokines; disease control; dogs; economic impact; immune response; immunization; immunoglobulin G; inflammation; jackfruits; lectins; lethal dose; livestock and meat industry; mice; morbidity; mortality; neosporosis; neuromuscular disorders; parasites; pathogens; reproductive disorders; splenocytes; vaccines
Abstract:
... ArtinM and Jacalin (JAC) are lectins from the jackfruit (Artocarpus integrifolia) that have important role in modulation of immune responses to pathogens. Neospora caninum is an Apicomplexa parasite that causes neuromuscular disease in dogs and reproductive disorders in cattle, with economic impact on the livestock industry. Hence, we evaluated the adjuvant effect of ArtinM and JAC in immunization ...
DOI:
10.1016/j.vaccine.2011.09.136

42. Bacillus Calmette-Guérin vaccination using a microneedle patch

Author:
Yasuhiro Hiraishi; Subhadra Nandakumar; Seong-O Choi; Jeong Woo Lee; Yeu-Chun Kim; James E. Posey; Suraj B. Sable; Mark R. Prausnitz
Source:
Vaccine 2011 v.29 no.14 pp. 2626-2636
ISSN:
0264-410X
Subject:
Mycobacterium bovis BCG; Mycobacterium tuberculosis; T-lymphocytes; antigens; developing countries; engineering; guinea pigs; health services; humans; immune response; infrastructure; interferon-gamma; lungs; lymphocyte proliferation; mortality; spleen; technology; tuberculosis; vaccination; vaccines
Abstract:
... Tuberculosis (TB) caused by Mycobacterium tuberculosis continues to be a leading cause of mortality among bacterial diseases, and the bacillus Calmette-Guérin (BCG) is the only licensed vaccine for human use against this disease. TB prevention and control would benefit from an improved method of BCG vaccination that simplifies logistics and eliminates dangers posed by hypodermic needles without co ...
DOI:
10.1016/j.vaccine.2011.01.042
PubMed:
21277407
PubMed Central:
PMC3127204

43. Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies

Author:
Kae Pusic; Hengyi Xu; Andrew Stridiron; Zoraida Aguilar; Andrew Wang; George Hui
Source:
Vaccine 2011 v.29 no.48 pp. 8898-8908
ISSN:
0264-410X
Subject:
Plasmodium falciparum; adjuvants; antibodies; antigens; blood; bone marrow; cytokines; dendritic cells; immune response; malaria; mechanism of action; merozoites; mice; nanoparticles; parasites; polypeptides; quantum dots; secretion; surface proteins; vaccines
Abstract:
... In this proof-of-concept study we report the use of <15nm, water soluble, inorganic nanoparticles as a vaccine delivery system for a blood stage malaria vaccine. The recombinant malarial antigen, Merozoite Surface Protein 1 (rMSP1) of Plasmodium falciparum served as the model vaccine. The rMSP1 was covalently conjugated to polymer-coated quantum dot CdSe/ZnS nanoparticles (QDs) via surface carboxy ...
DOI:
10.1016/j.vaccine.2011.09.070
PubMed:
21963870
PubMed Central:
PMC3202662

44. Borrelia burgdorferi BBA52 is a potential target for transmission blocking Lyme disease vaccine

Author:
Manish Kumar; Simarjot Kaur; Toru Kariu; Xiuli Yang; Ioannis Bossis; John F. Anderson; Utpal Pal
Source:
Vaccine 2011 v.29 no.48 pp. 9012-9019
ISSN:
0264-410X
Subject:
Borrelia burgdorferi; Lyme disease; antibodies; antigens; disulfide bonds; immune response; immunization; mice; ticks; vaccine development; vaccines
Abstract:
... The surface-exposed antigens of Borrelia burgdorferi represent important targets for induction of protective host immune responses. BBA52 is preferentially expressed by B. burgdorferi in the feeding tick, and a targeted deletion of bba52 interferes with vector–host transitions in vivo. In this study, we demonstrate that BBA52 is an outer membrane surface-exposed protein and that disulfide bridges ...
DOI:
10.1016/j.vaccine.2011.09.035
PubMed:
21945261
PubMed Central:
PMC3202674

45. CD4⁺CD25⁺ regulatory T cell-mediated changes in the expression of endocytic receptors and endocytosis process of human dendritic cells

Author:
Ana-Maria Navarrete; Sandrine Delignat; Jean-Luc Teillaud; Srini V. Kaveri; Sébastien Lacroix-Desmazes; Jagadeesh Bayry
Source:
Vaccine 2011 v.29 no.15 pp. 2649-2652
ISSN:
0264-410X
Subject:
T-lymphocytes; antigens; dendritic cells; endocytosis; humans; immune response; receptors; vaccination; vaccines
Abstract:
... CD4⁺CD25⁺ regulatory T cells (Tregs) are known to inhibit immune responses to antigens. Since, the process of antigen uptake by dendritic cells (DC) is central to induction of immune responses, we analyzed the effect of Tregs on the expression of endocytic receptors on DC and its repercussion on antigen uptake. Our results demonstrate that Tregs down-regulate the expression and uptake of antigens ...
DOI:
10.1016/j.vaccine.2011.01.095

46. Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen

Author:
Mauricio A. Arias; Andrew Loxley; Christy Eatmon; Griet Van Roey; David Fairhurst; Mark Mitchnick; Philip Dash; Tom Cole; Frank Wegmann; Quentin Sattentau; Robin Shattock
Source:
Vaccine 2011 v.29 no.6 pp. 1258-1269
ISSN:
0264-410X
Subject:
T-lymphocytes; adjuvants; antigens; blood serum; carnauba wax; humoral immunity; immune response; immunoglobulin A; immunoglobulin G; inflammation; mice; nanoparticles; vaccination; vaccine development; vaccines
Abstract:
... Induction of humoral responses to HIV at mucosal compartments without inflammation is important for vaccine design. We developed charged wax nanoparticles that efficiently adsorb protein antigens and are internalized by DC in the absence of inflammation. HIV-gp140-adsorbed nanoparticles induced stronger in vitro T-cell proliferation responses than antigen alone. Such responses were greatly enhance ...
DOI:
10.1016/j.vaccine.2010.11.084
PubMed:
21145913
PubMed Central:
PMC3098439

47. Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS

Author:
Elke S. Bergmann-Leitner; Patricia M. Legler; Tatyana Savranskaya; Christian F. Ockenhouse; Evelina Angov
Source:
Vaccine 2011 v.29 no.35 pp. 5940-5949
ISSN:
0264-410X
Subject:
Plasmodium berghei; antigens; cell-mediated immunity; hepatocytes; immune response; immunization; insects; liver; malaria; mechanism of action; mice; ookinetes; plasmids; sporozoites; vaccines
Abstract:
... The malarial protein CelTOS, for cell-traversal protein for ookinetes and sporozoites, from Plasmodium berghei has been shown to mediate malarial invasion of both vertebrate and insect host cells and is required for establishing their successful infections. In the vertebrate host, Plasmodium sporozoites traverse via a complex passage through cellular barriers in the skin and the liver sinusoid to ...
DOI:
10.1016/j.vaccine.2011.06.053

48. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis

Author:
Maria Agallou; Maritsa Margaroni; Evdokia Karagouni
Source:
Vaccine 2011 v.29 no.31 pp. 5053-5064
ISSN:
0264-410X
Subject:
Leishmania infantum; animal models; animal organs; antibodies; antigens; dendritic cells; immune response; immunoglobulin G; interleukin-10; interleukin-12; interleukin-17; membrane proteins; mice; oligodeoxyribonucleotides; parasite load; parasites; phenotype; screening; transforming growth factor beta; vaccination; vaccines; visceral leishmaniasis
Abstract:
... The use of dendritic cells (DCs) pulsed with defined Leishmania antigens could be a potential immune intervention tool for the induction of protection against infection. In the present study, bone marrow-derived DCs (BM-DCs) pulsed ex vivo with the peptide 12–31aa portion of kinetoplastid membrane protein (KMP)-11 (KMP-11₁₂–₃₁ₐₐ peptide) acquired a semimature phenotype expressing IL-12 and IL-10, ...
DOI:
10.1016/j.vaccine.2011.04.089

49. Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1

Author:
Felipe García; Jean-Pierre Routy
Source:
Vaccine 2011 v.29 no.38 pp. 6454-6463
ISSN:
0264-410X
Subject:
HIV infections; Human immunodeficiency virus 1; T-lymphocytes; animal models; antigens; antiretroviral agents; clinical trials; experts; immune response; monitoring; patients; vaccination; vaccines
Abstract:
... Therapeutic immunization has been proposed as an approach that might help limit the need for lifelong combined antiretroviral therapy (cART). One approach for therapeutic vaccination which has been explored during the last few years is the administration of autologous monocyte-derived DCs (MD-DCs) loaded ex vivo with a variety of antigens. It has been shown in experimental murine models as well as ...
DOI:
10.1016/j.vaccine.2011.07.043

50. Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines

Author:
Janny Westdijk; Debbie Brugmans; Javier Martin; Aart van’t Oever; Wilfried A.M. Bakker; Lonneke Levels; Gideon Kersten
Source:
Vaccine 2011 v.29 no.18 pp. 3390-3397
ISSN:
0264-410X
Subject:
antigens; humans; immune response; neutralization; rats; serotypes; vaccines; viruses
Abstract:
... GMP-batches of Sabin-IPV were characterized for their antigenic and immunogenic properties. Antigenic fingerprints of Sabin-IPV reveal that the D-antigen unit is not a fixed amount of antigen but depends on antibody and assay type. Instead of the D-antigen unit we propose standardization of IPV based on a combination of protein amount for dose and D-antigenicity for quality of the vaccine. Althoug ...
DOI:
10.1016/j.vaccine.2011.02.085